Pacira Pharmaceuticals announce second quarter financials

Pacira Pharmaceuticals Inc. announced $57 million in Exparel products revenue in the second quarter, representing a 27% increase over the same period last year, according to Dave Stack, president, CEO and chairman of the company.

In May, Pacira announced the completion of the end-of-review process with the FDA Division of Anesthesia, Analgesia and Addiction Products for the use of Exparel (bupivacaine) as a nerve block to provide postsurgical analgesia.

Also in May, the company announced data evaluating the use of Exparel in patients undergoing breast reconstruction.

Patients who received local infiltration with Exparel vs. preoperative paravertebral block for pain control following mastectomy with immediate tissue expander breast reconstruction reported lower pain scores and required less opioids and antiemetic medication for nausea.

Total revenues were $59.1 million in the second quarter of 2015, compared to $47.2 million in the second quarter of 2014, according to the press release.

Source: www.pacira.com